Aileron Therapeutics, Inc. (ALRN): Price and Financial Metrics

Aileron Therapeutics, Inc. (ALRN): $1.60

0.03 (+1.90%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add ALRN to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#325 of 474

in industry

ALRN Price/Volume Stats

Current price $1.60 52-week high $9.36
Prev. close $1.57 52-week low $1.12
Day low $1.55 Volume 16,500
Day high $1.60 Avg. volume 41,568
50-day MA $1.44 Dividend yield N/A
200-day MA $2.68 Market Cap 7.26M

ALRN Stock Price Chart Interactive Chart >


Aileron Therapeutics, Inc. (ALRN) Company Bio


Aileron Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, which represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The company's lead product candidate ALRN-6924 is being evaluated in multiple clinical trials. The company was founded in 2005 and is based in Cambridge, Massachusetts.


ALRN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALRN Latest Social Stream


Loading social stream, please wait...

View Full ALRN Social Stream

Latest ALRN News From Around the Web

Below are the latest news stories about AILERON THERAPEUTICS INC that investors may wish to consider to help them evaluate ALRN as an investment opportunity.

Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | April 4, 2023

Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo | March 14, 2023

Cancer drugmaker down to 3 employees after trial failure

A cancer firm has gone from a paltry nine employees to an even scanter three after a chemoprotective drug failed in clinical trials.

Yahoo | February 22, 2023

Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall

Aileron Therapeutics (NASDAQ: ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast cancer showed severe neutropenia (Grade 4) and alopecia (hair loss). The primary endpoint of the Phase 1b open-label trial was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or "TAC" chemotherapy, was the duration and incidence of severe neutropenia

Yahoo | February 21, 2023

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint of the Phase 1b open-label trial, which was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, a

Yahoo | February 21, 2023

Read More 'ALRN' Stories Here

ALRN Price Returns

1-mo 7.95%
3-mo 17.65%
6-mo -36.25%
1-year -81.54%
3-year -93.28%
5-year -98.51%
YTD -32.49%
2022 -78.95%
2021 -45.88%
2020 81.50%
2019 -31.79%
2018 -92.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!